Abstract
SARS-CoV-2 genetic diversity has the potential to impact the virus transmissibility and the escape from natural infection- or vaccine-elicited neutralizing antibodies. Here, we report the emergence of the B.1.621 lineage, considered a variant of interest (VOI) with the accumulation of several mutations affecting the Spike protein, including the amino acid changes I95I, Y144T, Y145S and the insertion 146N in the N-terminal domain, R346K, E484K and N501Y in the Receptor Binding Domain and P681H in the S1/S2 cleavage site of the Spike protein. The rapid increase in frequency and fixation in a relatively short time in some cities that were near the theoretical herd immunity suggests an epidemiologic impact. Further studies will be required to assess the biological and epidemiologic roles of the substitution pattern found in the B.1.621 lineage.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was funded by the Project CEMIN-4-2020 Instituto Nacional de Salud. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Good morning, dear reviewers, the ethical considerations were clarified in the body of manuscript because it was approved by the ethics committee of the National Institute of Health of Colombia within the framework of the Cemin 4 project. The circulation of the new variant of SARS-CoV-2 has been disclosed nationwide with an official statement (attached) because my Institution is the national authority on public health. We are also waiting for the lineage assignment by the PANGOLIN tool: https://github.com/cov-lineages/pango-designation/issues/23 I kindly require the acceptance of the preprint as soon as possible for its scientific divulgation that includes genetic characterization. Thank you very much for your prompt response. Regards
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data is available in GISAID database, the phylogenetic analysis is available in a microreact site https://microreact.org/project/5CAiK3qCMaEgE4vYkKVpZW/b7113efc.
https://microreact.org/project/5CAiK3qCMaEgE4vYkKVpZW/b7113efc.
